Ni Libin, Yan Yingzhao, Fu Yang, Sheng Jing, Qu Hangbo, Ru Xuanliang
Department of Orthopaedic Surgery, Zhejiang Hospital, 1229 Gudun Rd, 310013, Hangzhou, Zhejiang, China.
J Orthop. 2024 Feb 15;52:85-89. doi: 10.1016/j.jor.2024.02.002. eCollection 2024 Jun.
To retrospectively explore the effect of a half-dose buprenorphine transdermal patch for analgesia after arthroscopic rotator cuff repair (ARCR).
This analysis was performed with clinical data from patients who received unilateral ARCR in our hospital between October 2017 and December 2020. The patients were divided into three groups (30 cases each). In group A (control group), 100 mg flurbiprofen axetil (FA) was administered twice a day for 5 days after surgery. In group B (experimental group), 100 mg FA was administered twice a day for 5 days and half (2.5 mg) of a buprenorphine transdermal patch was applied after surgery; an additional half (2.5 mg) patch was applied 3 days later. In group C (condition control group), 100 mg FA was administered twice a day for 5 days and a 5-mg patch was applied directly after surgery. The visual analog scale (VAS) was administered repeatedly 1 day before surgery and 1, 2, 3, 5, and 14 days after surgery in each group. The simple shoulder test (SST) score, range of shoulder forward elevation (FE), and external rotation (ER) were recorded preoperatively and 12 weeks postoperatively.
VAS scores on postoperative days 3 and 5 were significantly lower in groups B and C than in group A ( < 0.05). The VAS score on postoperative day 14 was significantly lower in group C than in group A ( < 0.05). The difference in VAS score between groups B and C was not significant ( > 0.05). All patients had significantly improved VAS scores, SST scores, FE, and ER at 12 weeks postoperatively.
The half-dose buprenorphine transdermal patch had a good analgesic effect with minimal side effects after ARCR and did not delay the recovery of shoulder joint function.
回顾性探讨半剂量丁丙诺啡透皮贴剂用于关节镜下肩袖修补术(ARCR)后镇痛的效果。
本分析采用2017年10月至2020年12月在我院接受单侧ARCR患者的临床资料。将患者分为三组(每组30例)。A组(对照组)术后5天每天两次给予100mg氟比洛芬酯(FA)。B组(实验组)术后5天每天两次给予100mg FA,术后应用半片(2.5mg)丁丙诺啡透皮贴剂;3天后再应用半片(2.5mg)贴剂。C组(条件对照组)术后5天每天两次给予100mg FA,术后直接应用5mg贴剂。每组在术前1天以及术后1、2、3、5和14天重复进行视觉模拟评分(VAS)。术前及术后12周记录简单肩关节试验(SST)评分、肩关节前屈(FE)范围和外旋(ER)。
B组和C组术后第3天和第5天的VAS评分显著低于A组(<0.05)。C组术后第14天的VAS评分显著低于A组(<0.05)。B组和C组之间的VAS评分差异不显著(>0.05)。所有患者术后12周时VAS评分、SST评分、FE和ER均有显著改善。
半剂量丁丙诺啡透皮贴剂在ARCR后具有良好的镇痛效果,副作用最小,且不延迟肩关节功能恢复。